ERIS - Swing Trade Analysis

Last Updated Time : 02 Aug 25, 12:58 am

Swing Trade Rating: 3.5

Here’s a detailed swing trade analysis of ERIS, considering both its momentum and valuation profile

📊 Snapshot Summary

Valuation: P/E of 69.8 vs industry average of 34.0 → Significantly overvalued

PEG Ratio: -14.2 → Suggests questionable growth valuation alignment

ROCE/ROE: 12.2% / 12.9% → Moderate capital efficiency

Debt-to-Equity: 0.87 → Relatively high leverage

PAT Growth (QoQ): 32.1% → Strong quarterly earnings momentum

RSI: 61.0 → Approaching overbought territory

MACD: 32.3 → Strong bullish trend

DMA Comparison: Price above 50-DMA and 200-DMA → Short-term bullish

Volume: Below weekly average → Weak participation in current uptrend

⚖️ Swing Trade Setup

ERIS is currently riding a bullish wave, but the technicals suggest it’s getting a bit frothy.

Overvaluation and high debt make it less ideal for swing trading, especially at current levels.

RSI nearing 70 and decreasing volume hint that the rally could soon lose steam.

✅ Optimal Entry Zone

Suggested Buy Range: ₹1,665–₹1,680 Near the 50-DMA for a lower-risk entry in case of a pullback.

🚪 Exit Strategy

Resistance/Exit Zone: ₹1,850–₹1,875 Look to book profits before it nears the 52-week high.

Stop-Loss: ₹1,640 (just below 50-DMA support) to protect downside risk.

Would you like a comparison to other pharma midcaps or stocks with stronger momentum and more attractive valuation? That could help refine your swing strategy.

Edit in a page